HilleVax Shares Rise After Announcing Job Cuts, Executive Departures

Dow Jones2024-12-05

By Connor Hart

Shares of HilleVax gained after it said it will cut about 70% of its workforce, or about 28 jobs, and that several executives were leaving the company.

The stock jumped 16%, to $2.16, in after-hours trading Thursday. Shares ended the day 2.6% lower, at $1.87, putting them down 88% since the beginning of the year.

The Boston-based biopharmaceutical company said its job cuts, which are likely to be substantially complete by the end of January, will reduce operating expenses. It previously cut 15 jobs, or about 25% of its workforce, in October.

It expects to incur about $6.1 million in charges associated with the current round of layoffs, primarily from employee severance payments, benefits and related termination costs. The majority of these charges will be recognized in the fourth quarter of this year, the company said.

HilleVax's remaining workers will continue to explore and evaluate the development of its norovirus vaccine candidates, as well as business development-related activities for these vaccine candidates and other strategic alternatives, it said.

Also on Thursday, the company said Chief Operating Officer Sean McLoughlin, Chief Medical Officer Astrid Borkowski and Chief Business Officer Aditya Kohli will leave their respective roles, effective Dec. 19.

At that point, McLoughlin and Kohli will transition to consultant roles on an hourly, as-needed basis. Borkowski will remain a non-executive employee through Sept. 30, 2025.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

December 05, 2024 18:41 ET (23:41 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2489443678?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2024-12-06 07:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2489443678","market":"hk","top_or_hot":-1,"title":"HilleVax Shares Rise After Announcing Job Cuts, Executive Departures","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of HilleVax gained after it said it will cut about 70% of its workforce, or about 28 jobs, and that several executives were leaving the company. \n</p>\n<p>\n  The stock jumped 16%, to $2.16, in after-hours trading Thursday. Shares ended the day 2.6% lower, at $1.87, putting them down 88% since the beginning of the year. \n</p>\n<p>\n  The Boston-based biopharmaceutical company said its job cuts, which are likely to be substantially complete by the end of January, will reduce operating expenses. It previously cut 15 jobs, or about 25% of its workforce, in October. \n</p>\n<p>\n  It expects to incur about $6.1 million in charges associated with the current round of layoffs, primarily from employee severance payments, benefits and related termination costs. The majority of these charges will be recognized in the fourth quarter of this year, the company said. \n</p>\n<p>\n  HilleVax's remaining workers will continue to explore and evaluate the development of its norovirus vaccine candidates, as well as business development-related activities for these vaccine candidates and other strategic alternatives, it said. \n</p>\n<p>\n  Also on Thursday, the company said Chief Operating Officer Sean McLoughlin, Chief Medical Officer Astrid Borkowski and Chief Business Officer Aditya Kohli will leave their respective roles, effective Dec. 19. \n</p>\n<p>\n  At that point, McLoughlin and Kohli will transition to consultant roles on an hourly, as-needed basis. Borkowski will remain a non-executive employee through Sept. 30, 2025. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 05, 2024 18:41 ET (23:41 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HilleVax Shares Rise After Announcing Job Cuts, Executive Departures</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHilleVax Shares Rise After Announcing Job Cuts, Executive Departures\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-06 07:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of HilleVax gained after it said it will cut about 70% of its workforce, or about 28 jobs, and that several executives were leaving the company. \n</p>\n<p>\n  The stock jumped 16%, to $2.16, in after-hours trading Thursday. Shares ended the day 2.6% lower, at $1.87, putting them down 88% since the beginning of the year. \n</p>\n<p>\n  The Boston-based biopharmaceutical company said its job cuts, which are likely to be substantially complete by the end of January, will reduce operating expenses. It previously cut 15 jobs, or about 25% of its workforce, in October. \n</p>\n<p>\n  It expects to incur about $6.1 million in charges associated with the current round of layoffs, primarily from employee severance payments, benefits and related termination costs. The majority of these charges will be recognized in the fourth quarter of this year, the company said. \n</p>\n<p>\n  HilleVax's remaining workers will continue to explore and evaluate the development of its norovirus vaccine candidates, as well as business development-related activities for these vaccine candidates and other strategic alternatives, it said. \n</p>\n<p>\n  Also on Thursday, the company said Chief Operating Officer Sean McLoughlin, Chief Medical Officer Astrid Borkowski and Chief Business Officer Aditya Kohli will leave their respective roles, effective Dec. 19. \n</p>\n<p>\n  At that point, McLoughlin and Kohli will transition to consultant roles on an hourly, as-needed basis. Borkowski will remain a non-executive employee through Sept. 30, 2025. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 05, 2024 18:41 ET (23:41 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HLVX","symbol_name":"HilleVax, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2489443678","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489443678","pubTimestamp":1733442060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of HilleVax gained after it said it will cut about 70% of its workforce, or about 28 jobs, and that several executives were leaving the company.The stock jumped 16%, to $2.16, in after-hours trading Thursday. Shares ended the day 2.6% lower, at $1.87, putting them down 88% since the beginning of the year.The Boston-based biopharmaceutical company said its job cuts, which are likely to be substantially complete by the end of January, will reduce operating expenses. It previously cut 15 jobs, or about 25% of its workforce, in October.It expects to incur about $6.1 million in charges associated with the current round of layoffs, primarily from employee severance payments, benefits and related termination costs. The majority of these charges will be recognized in the fourth quarter of this year, the company said.HilleVax's remaining workers will continue to explore and evaluate the development of its norovirus vaccine candidates, as well as business development-related activities fo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HLVX":"HilleVax, Inc.","BK4139":"生物科技"},"translate_title":"HilleVax宣布裁员、高管离职后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HLVX":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of HilleVax gained after it said it will cut about 70% of its workforce, or about 28 jobs, and that several executives were leaving the company. \n\n\n  The stock jumped 16%, to $2.16, in after-hours trading Thursday. Shares ended the day 2.6% lower, at $1.87, putting them down 88% since the beginning of the year. \n\n\n  The Boston-based biopharmaceutical company said its job cuts, which are likely to be substantially complete by the end of January, will reduce operating expenses. It previously cut 15 jobs, or about 25% of its workforce, in October. \n\n\n  It expects to incur about $6.1 million in charges associated with the current round of layoffs, primarily from employee severance payments, benefits and related termination costs. The majority of these charges will be recognized in the fourth quarter of this year, the company said. \n\n\n  HilleVax's remaining workers will continue to explore and evaluate the development of its norovirus vaccine candidates, as well as business development-related activities for these vaccine candidates and other strategic alternatives, it said. \n\n\n  Also on Thursday, the company said Chief Operating Officer Sean McLoughlin, Chief Medical Officer Astrid Borkowski and Chief Business Officer Aditya Kohli will leave their respective roles, effective Dec. 19. \n\n\n  At that point, McLoughlin and Kohli will transition to consultant roles on an hourly, as-needed basis. Borkowski will remain a non-executive employee through Sept. 30, 2025. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 05, 2024 18:41 ET (23:41 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489443678"}